Fosun Pharma Unit Gets China Nod for Tumor Imaging Drug Trial

MT Newswires Live
Yesterday

Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) unit Chengdu StarRay Therapeutics obtained clinical trial approval for [18F]F-SR031 injection from China's National Medical Products Administration.

The drug will be tested for positron emission tomography imaging of fibroblast activation protein-positive lesions in patients with solid tumors, a Monday bourse filing showed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10